

Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) - Global Forecast to 2029

<https://marketpublishers.com/r/G2EAA40F9BF6EN.html>

Date: January 2025

Pages: 525

Price: US\$ 4,950.00 (Single User License)

ID: G2EAA40F9BF6EN

Abstracts

The global gene transfer technologies market is projected to surpass USD 5.93 billion in 2029 from USD 3.73 billion in 2024, with a significant CAGR of 9.7%. Increasing demand for personalized medicines, along with advancements in cell and gene therapies, continues to grow and contribute to a rise in this market. In addition, the increased application of gene transfer technologies in vaccine development and cancer immunotherapy boosts the segmental growth.

“The viral vector gene transfer technologies segment accounted for the largest share in 2023.”

On the basis of mode, the gene transfer technologies market is further segmented into viral vector and non-viral vector. The viral vector segment is retrovirus, adenovirus, adeno associated virus (AAV) and other virus vector. The viral vector segment dominated the market in 2023, owing to superior safety and efficacy profile, minimal immunogenicity and advancements in AAV engineering.

“By application, the therapeutic application segment accounted for the largest share in the gene transfer technologies market.”

The application segment in the gene transfer technologies market is segmented into research application, therapeutic application and applications. The research application is segmented into drug discovery & development and other research application.

Similarly the therapeutic application further divided into gene therapy, cell therapy, vaccines and other therapeutic application. The therapeutic application dominated the segment owing to advancements in gene transfer technologies, such as improved adeno-associated virus (AAV) & lentiviral vector and expanding application of gene therapy in cardiovascular, neurological and metabolic diseases.

“North America: the largest share of the gene transfer technologies market”

By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the gene transfer technologies market in 2023 and likely continue dominance during the forecast period. Presence of dominant market players in gene transfer technologies companies in the region, strong base of gene transfer technologies manufacturers such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany) are some of the prominent factors accelerating market growth.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the gene transfer technologies market.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc. (US), Genscript (US), Bio-Techne (US), Lonza (Switzerland), Takara Bio, Inc. (Japan), Promega Corporation (US), Oxford Biomedica plc (UK) and MaxCyte (US)) are some of the major players operating in the gene transfer technologies market.

Research Coverage:

Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus,...

This research report categorizes the gene transfer technologies market product (instruments, consumables, reagents, kits & assays and other products), mode (viral vector and non viral vector), method (ex vivo, in vivo and in vitro), application (research, therapeutic and other application) end user (pharmaceutical & biotechnology companies, academic & research institutes and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the gene transfer technologies market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the gene transfer technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene transfer technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Growing demand for personalized medicines and cell & gene therapies, Increased investments in gene therapy research, Expanding applications in vaccine development & cancer immunotherapy), restraints (High costs of gene transfer systems), opportunities (Advancements in gene editing technologies and nanotechnology, Integration with digital technologies such as AI and ML) and Challenges (Scalability of production).

Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for gene transfer technologies.

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene transfer technologies market

Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany) and among others in the market.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
 - 1.3.2 INCLUSIONS & EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
 - 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
 - 2.2.1 MARKET ESTIMATION
 - 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
 - 2.2.3 TOP-DOWN APPROACH
- 2.3 MARKET GROWTH RATE PROJECTION
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 GENE DELIVERY TECHNOLOGIES MARKET OVERVIEW
- 4.2 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION (2023)
- 4.3 GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY MODE, 2024 VS. 2029
- 4.4 GENE DELIVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Growing demand for personalized medicine and cell & gene therapies

5.2.1.2 Increased investments in gene therapy research

5.2.1.3 Expanding applications in vaccine development & cancer immunotherapy

5.2.2 RESTRAINTS

5.2.2.1 High costs of gene delivery systems

5.2.3 OPPORTUNITIES

5.2.3.1 Advancements in gene editing technologies & nanotechnology

5.2.3.2 Integration with digital technologies such as AI & ML

5.2.4 CHALLENGES

5.2.4.1 Scalability of production

5.3 ECOSYSTEM ANALYSIS

5.3.1 PRODUCT PROVIDERS

5.3.2 END USERS

5.3.3 REGULATORY BODIES

5.4 TECHNOLOGY ANALYSIS

5.4.1 KEY TECHNOLOGIES

5.4.1.1 Microinjection

5.4.1.2 Electroporation

5.4.1.3 Sonoporation

5.4.2 COMPLEMENTARY TECHNOLOGIES

5.4.2.1 Gene editing technologies

5.4.2.2 Bioinformatics and computational tools

5.4.3 ADJCENT TECHNOLOGIES

5.4.3.1 Nanotechnology and nano-carriers

5.5 PRICING ANALYSIS

5.5.1 AVERAGE SELLING PRICE TREND OF REAGENTS/CONSUMABLES, BY KEY PLAYER

5.5.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION

5.6 VALUE CHAIN ANALYSIS

5.7 SUPPLY CHAIN ANALYSIS

5.8 PATENT ANALYSIS

5.9 TRADE ANALYSIS

5.9.1 IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)

5.9.2 EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)

5.10 KEY CONFERENCES AND EVENTS, 2024–2025

5.11 REGULATORY LANDSCAPE

5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.11.2 REGULATORY FRAMEWORK

5.11.2.1 North America

5.11.2.2 Europe

5.11.2.3 Asia Pacific

5.11.2.4 Rest of the World

5.12 PORTER'S FIVE FORCES ANALYSIS

5.12.1 THREAT OF NEW ENTRANTS

5.12.2 THREAT OF SUBSTITUTES

5.12.3 BARGAINING POWER OF BUYERS

5.12.4 BARGAINING POWER OF SUPPLIERS

5.12.5 INTENSITY OF COMPETITIVE RIVALRY

5.13 KEY STAKEHOLDERS AND BUYING CRITERIA

5.13.1 KEY STAKEHOLDERS

5.13.2 BUYING CRITERIA

5.14 INVESTMENT AND FUNDING SCENARIO

5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.16 IMPACT OF AI/GEN AI ON GENE DELIVERY TECHNOLOGIES MARKET

6 GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT

6.1 INTRODUCTION

6.2 REAGENTS, KITS, AND ASSAYS

6.2.1 INCREASING DEMAND FOR TRANSFECTION AND GENE EDITING TOOLS TO DRIVE MARKET GROWTH

6.3 CONSUMABLES

6.3.1 RISING R&D ACTIVITY TO SUPPORT DEMAND GROWTH

6.4 INSTRUMENTS

6.4.1 INCREASING ADOPTION OF ELECTROPORATION DEVICES TO DRIVE MARKET

6.5 OTHER PRODUCTS

7 GENE DELIVERY TECHNOLOGIES MARKET, BY MODE

7.1 INTRODUCTION

7.2 VIRAL VECTORS

7.2.1 RETROVIRUSES

7.2.1.1 Lentiviruses

7.2.1.1.1 Rising disease incidence to drive market

7.2.1.2 Other retroviruses

7.2.2 ADENOVIRUSES

7.2.2.1 Expansion of vaccination programs to propel market growth

7.2.3 ADENO-ASSOCIATED VIRUSES

7.2.3.1 Low immunogenicity of AAV vectors to support adoption

7.2.4 OTHER VIRAL VECTORS

7.3 NON-VIRAL VECTORS

7.3.1 CHEMICAL METHODS

7.3.2 LIPOSOME-MEDIATED

7.3.2.1 High efficiency and compatibility to drive market

7.3.3 CALCIUM PHOSPHATE

7.3.3.1 Increasing R&D in cell-based therapies to propel market growth

7.3.4 DEAE-DEXTRAN

7.3.4.1 Simplicity and cost-effectiveness to support adoption

7.3.5 CATIONIC POLYMERS

7.3.5.1 Advancements in cationic polymer technology to drive market

7.3.6 OTHER CHEMICAL METHODS

7.4 PHYSICAL METHODS

7.4.1 ELECTROPORATION

7.4.1.1 Rising demand for effective cell transfection technologies to drive market

7.4.2 MICROINJECTION

7.4.2.1 High accuracy and control and potential for tailored delivery to drive market

7.4.3 GENE GUNS

7.4.3.1 High efficiency of gene guns in transfecting various cell types to drive market

7.4.4 OTHER PHYSICAL METHODS

8 GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD

8.1 INTRODUCTION

8.2 IN VIVO

8.2.1 EMERGENCE OF MRNA-BASED VACCINES TO PROPEL IN VIVO GENE DELIVERY APPLICATIONS

8.3 EX VIVO

8.3.1 SUCCESSFUL COMMERCIALIZATION OF CAR T-CELL THERAPIES TO

DRIVE THE EX VIVO GENE DELIVERY MARKET

8.4 IN VITRO

8.4.1 DATABASES MAJORLY CONTRIBUTE TO STORING GENE DELIVERY TECHNOLOGIES AND INTEGRATING OTHER OMICS DATABASES.

9 GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION

9.1 INTRODUCTION

9.2 THERAPEUTIC APPLICATIONS

9.2.1 GENE THERAPY

9.2.1.1 Increasing demand for personalized medicine to support market growth

9.2.2 CELL THERAPY

9.2.2.1 Rising government funding to propel market growth

9.2.3 VACCINES

9.2.3.1 Rising prevalence of infectious diseases to drive market growth

9.2.4 OTHER THERAPEUTIC APPLICATIONS

9.3 RESEARCH APPLICATIONS

9.3.1 DRUG DISCOVERY & DEVELOPMENT

9.3.1.1 Increased funding for gene therapy research to drive market growth

9.3.1.2 Cancer

9.3.1.2.1 Rising investment in cancer research to drive market

9.3.2 INFECTIOUS DISEASES

9.3.2.1 Rising incidence of infectious disease to drive market growth

9.3.3 GENETIC & NEUROLOGICAL DISORDERS

9.3.3.1 Rising burden of disorders to drive market

9.3.4 AUTOIMMUNE DISEASES

9.3.4.1 Growing prevalence of autoimmune disorders to ensure demand for therapeutic solutions

9.3.5 OTHER DISEASES

9.3.6 OTHER RESEARCH APPLICATIONS

9.4 OTHER APPLICATIONS

10 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER

10.1 INTRODUCTION

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET

10.3 ACADEMIC & RESEARCH INSTITUTES

10.3.1 INCREASING R&D AND GROWING FUNDING AND PARTNERSHIPS TO PROMOTE MARKET GROWTH

10.4 OTHER END USERS

11 GENE DELIVERY TECHNOLOGIES MARKET, BY REGION

11.1 INTRODUCTION

11.2 NORTH AMERICA

11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK

11.2.2 US

11.2.2.1 US to dominate North American market over forecast period

11.2.3 CANADA

11.2.3.1 Strong infrastructure and availability of funding for biomedical research to support market growth

11.3 EUROPE

11.3.1 EUROPE: MACROECONOMIC OUTLOOK

11.3.2 GERMANY

11.3.2.1 Germany to hold largest market share in Europe

11.3.3 UK

11.3.3.1 Increasing government funding to drive market growth

11.3.4 FRANCE

11.3.4.1 Rising support for genetic research to offer potential growth opportunities

11.3.5 ITALY

11.3.5.1 Rising R&D and support for gene delivery to drive market

11.3.6 SPAIN

11.3.6.1 Growing expansion of research centers to stimulate market

11.3.7 REST OF EUROPE

11.4 ASIA PACIFIC

11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK

11.4.2 CHINA

11.4.2.1 Increasing R&D expenditure to drive market growth

11.4.3 JAPAN

11.4.3.1 Rising research into precision medicine to support market growth

11.4.4 INDIA

11.4.4.1 Strong research base and rising FDI in pharma sector to support market growth

11.4.5 SOUTH KOREA

11.4.5.1 Alliances & investments in research to drive market

11.4.6 AUSTRALIA

- 11.4.6.1 Increasing focus on precision medicine to offer significant growth opportunities
- 11.4.7 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
 - 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
 - 11.5.2 BRAZIL
 - 11.5.2.1 Brazil to hold largest market share in LATAM
 - 11.5.3 MEXICO
 - 11.5.3.1 Strong pharmaceutical industry and increased government support to augment market growth
 - 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST
 - 11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
 - 11.6.2 GCC COUNTRIES
 - 11.6.2.1 Saudi Arabia
 - 11.6.2.1.1 Increasing government investments in healthcare and growing pharmaceuticals industry to support market
 - 11.6.2.2 UAE
 - 11.6.2.2.1 Growing R&D expenditure and infrastructural development to drive market
 - 11.6.2.3 Rest of GCC Countries
 - 11.6.3 REST OF MIDDLE EAST
- 11.7 AFRICA
 - 11.7.1 RISING EMPHASIS ON GENE DELIVERY TECHNOLOGIES FOR THERAPEUTICS TO SUPPORT MARKET GROWTH
 - 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

- 12.1 OVERVIEW
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
 - 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET
- 12.3 REVENUE ANALYSIS
- 12.4 MARKET SHARE ANALYSIS
- 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
 - 12.5.1 STARS
 - 12.5.2 EMERGING LEADERS
 - 12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023

12.5.5.1 Company footprint

12.5.5.2 Region footprint

12.5.5.3 Product footprint

12.5.5.4 Method footprint

12.5.5.5 Application footprint

12.5.5.6 End-user footprint

12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023

12.6.1 PROGRESSIVE COMPANIES

12.6.2 RESPONSIVE COMPANIES

12.6.3 DYNAMIC COMPANIES

12.6.4 STARTING BLOCKS

12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023

12.7 COMPANY VALUATION & FINANCIAL METRICS

12.7.1 FINANCIAL METRICS

12.7.2 COMPANY VALUATION

12.8 BRAND/PRODUCT COMPARISON

12.9 COMPETITIVE SCENARIO

12.9.1 PRODUCT LAUNCHES

12.9.2 DEALS

12.9.3 EXPANSIONS

13 COMPANY PROFILES

13.1 KEY PLAYERS

13.1.1 THERMO FISHER SCIENTIFIC INC.

13.1.1.1 Business overview

13.1.1.2 Products/Services/Solutions offered

13.1.1.3 Recent developments

13.1.1.3.1 Product launches

13.1.1.3.2 Expansions

13.1.1.4 MnM view

13.1.1.4.1 Key strengths

13.1.1.4.2 Strategic choices

13.1.1.4.3 Weaknesses and competitive threats

13.1.2 DANAHER CORPORATION

13.1.2.1 Business overview

13.1.2.2 Products/Services/Solutions offered

- 13.1.2.3 Recent developments
 - 13.1.2.3.1 Product launches
 - 13.1.2.3.2 Deals
 - 13.1.2.3.3 Expansions
- 13.1.2.4 MnM view
 - 13.1.2.4.1 Key strengths
 - 13.1.2.4.2 Strategic choices
 - 13.1.2.4.3 Weaknesses and competitive threats
- 13.1.3 MERCK KGAA
 - 13.1.3.1 Business overview
 - 13.1.3.2 Products/Services/Solutions offered
 - 13.1.3.3 Recent developments
 - 13.1.3.3.1 Deals
 - 13.1.3.3.2 Expansions
 - 13.1.3.4 MnM view
 - 13.1.3.4.1 Key strengths
 - 13.1.3.4.2 Strategic choices
 - 13.1.3.4.3 Weaknesses and competitive threats
- 13.1.4 BIO-RAD LABORATORIES, INC.
 - 13.1.4.1 Business overview
 - 13.1.4.2 Products/Services/Solutions offered
- 13.1.5 AGILENT TECHNOLOGIES, INC.
 - 13.1.5.1 Business overview
 - 13.1.5.2 Products/Services/Solutions offered
 - 13.1.5.3 Recent developments
 - 13.1.5.3.1 Deals
- 13.1.6 REVVITY
 - 13.1.6.1 Business overview
 - 13.1.6.2 Products/Services/Solutions offered
 - 13.1.6.3 Recent developments
 - 13.1.6.3.1 Product launches
 - 13.1.6.3.2 Deals
- 13.1.7 QIAGEN
 - 13.1.7.1 Business overview
 - 13.1.7.2 Products/Services/Solutions offered
- 13.1.8 GENSCRIPT
 - 13.1.8.1 Business overview
 - 13.1.8.2 Products/Services/Solutions offered
 - 13.1.8.3 Recent developments

- 13.1.8.3.1 Deals
- 13.1.9 TAKARA BIO INC.
 - 13.1.9.1 Business overview
 - 13.1.9.2 Products/Services/Solutions offered
 - 13.1.9.3 Recent developments
 - 13.1.9.3.1 Product launches
 - 13.1.9.3.2 Deals
- 13.1.10 PROMEGA CORPORATION
 - 13.1.10.1 Business overview
 - 13.1.10.2 Products/Services/Solutions offered
- 13.1.11 BIO-TECHNE
 - 13.1.11.1 Business overview
 - 13.1.11.2 Products/Services/Solutions offered
 - 13.1.11.3 Recent developments
 - 13.1.11.3.1 Product launches
- 13.1.12 LONZA
 - 13.1.12.1 Business overview
 - 13.1.12.2 Products/Services/Solutions offered
 - 13.1.12.3 Recent developments
 - 13.1.12.3.1 Product launches
 - 13.1.12.3.2 Deals
- 13.1.13 OXFORD BIOMEDICA PLC
 - 13.1.13.1 Business overview
 - 13.1.13.2 Products/Services/Solutions offered
 - 13.1.13.3 Recent developments
 - 13.1.13.3.1 Product launches
 - 13.1.13.3.2 Deals
 - 13.1.13.3.3 Other developments
- 13.1.14 SARTORIUS AG
 - 13.1.14.1 Business overview
 - 13.1.14.2 Products/Services/Solutions offered
 - 13.1.14.3 Recent developments
 - 13.1.14.3.1 Product launches
 - 13.1.14.3.2 Deals
- 13.1.15 MAXCYTE
 - 13.1.15.1 Business overview
 - 13.1.15.2 Products/Services/Solutions offered
 - 13.1.15.3 Recent developments
 - 13.1.15.3.1 Deals

13.2 OTHER PLAYERS

13.2.1 CELL BIOLABS, INC.

13.2.2 GENTARGET INC.

13.2.3 ORIGENE TECHNOLOGIES, INC.

13.2.4 ALTOGEN BIOSYSTEMS

13.2.5 OZ BIOSCIENCES

13.2.6 GENECOPOEIA, INC.

13.2.7 CREATIVE BIOLABS

13.2.8 SYN BIO TECHNOLOGIES LLC

13.2.9 SYSTEM BIOSCIENCES, LLC

13.2.10 VECTORBUILDER INC.

14 APPENDIX

14.1 DISCUSSION GUIDE

14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

14.3 CUSTOMIZATION OPTIONS

14.4 RELATED REPORTS

14.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS

TABLE 2 GENE DELIVERY TECHNOLOGIES MARKET: RISK ASSESSMENT ANALYSIS

TABLE 3 GENE DELIVERY TECHNOLOGY MARKET: KEY PRODUCT PROVIDERS

TABLE 4 GENE DELIVERY TECHNOLOGY MARKET: KEY END USERS

TABLE 5 GENE DELIVERY TECHNOLOGY MARKET: REGULATORY BODIES

TABLE 6 AVERAGE SELLING PRICE TREND OF GENE DELIVERY REAGENTS/CONSUMABLES, BY KEY PLAYERS, 2021–2023

TABLE 7 KEY PATENTS IN GENE DELIVERY TECHNOLOGIES MARKET, 2021–2024

TABLE 8 IMPORT VOLUME FOR HS CODE 854330, 2019–2023 (UNITS)

TABLE 9 EXPORT VOLUME FOR HS CODE 854330, 2019–2023 (UNITS)

TABLE 10 GENE DELIVERY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES & EVENTS

TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15 GENE DELIVERY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS

TABLE 17 GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 18 GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 19 NORTH AMERICA: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 20 EUROPE: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 21 ASIA PACIFIC: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 22 LATIN AMERICA: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 23 MIDDLE EAST: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 24 GCC COUNTRIES: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 25 GENE DELIVERY CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 26 NORTH AMERICA: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 27 EUROPE: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 28 ASIA PACIFIC: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 29 LATIN AMERICA: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 30 MIDDLE EAST: GENE DELIVERY CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 31 GCC COUNTRIES: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 32 GENE DELIVERY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 33 NORTH AMERICA: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 34 EUROPE: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 35 ASIA PACIFIC: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 36 LATIN AMERICA: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 37 MIDDLE EAST: GENE DELIVERY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 38 GCC COUNTRIES: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 39 OTHER GENE DELIVERY PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 40 OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 41 EUROPE: OTHER GENE DELIVERY PRODUCTS MARKET, BY

COUNTRY, 2022–2029 (USD MILLION)

TABLE 42 ASIA PACIFIC: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 43 LATIN AMERICA: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 44 MIDDLE EAST: OTHER GENE DELIVERY PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 45 GCC COUNTRIES: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 46 GENE DELIVERY TECHNOLOGIES MARKET BY MODE, 2022–2029 (USD MILLION)

TABLE 47 VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 48 VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 49 NORTH AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 50 EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 51 ASIA PACIFIC: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 52 LATIN AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 53 MIDDLE EAST: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 54 GCC COUNTRIES: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 55 RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 56 RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 57 NORTH AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 58 EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 59 ASIA PACIFIC: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 60 LATIN AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 61 MIDDLE EAST: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 62 GCC COUNTRIES: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 63 LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 64 NORTH AMERICA: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 65 EUROPE: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 66 ASIA PACIFIC: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 67 LATIN AMERICA: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 68 MIDDLE EAST: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 69 GCC COUNTRIES: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 70 OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 71 NORTH AMERICA: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 72 EUROPE: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 73 ASIA PACIFIC: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 74 LATIN AMERICA: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 75 MIDDLE EAST: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 76 GCC COUNTRIES: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 77 ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 78 NORTH AMERICA: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 79 EUROPE: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 80 ASIA PACIFIC: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 81 LATIN AMERICA: ADENOVIRUS-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 82 MIDDLE EAST: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 83 GCC COUNTRIES: ADENOVIRUS-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 84 AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)

TABLE 85 NORTH AMERICA: AAV-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 86 EUROPE: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY

COUNTRY, 2022–2029 (USD MILLION)

TABLE 87 ASIA PACIFIC: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 88 LATIN AMERICA: AAV-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 89 MIDDLE EAST: AAV-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 90 GCC COUNTRIES: AAV-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 91 OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 92 NORTH AMERICA: OTHER VIRAL VECTOR-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 93 EUROPE: OTHER VIRAL VECTOR-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 94 ASIA PACIFIC: OTHER VIRAL VECTOR-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 95 LATIN AMERICA: OTHER VIRAL VECTOR-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 96 MIDDLE EAST: OTHER VIRAL VECTOR-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 97 GCC COUNTRIES: OTHER VIRAL VECTOR-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 98 NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 99 NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 100 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 101 EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 102 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 103 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 104 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 105 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 106 CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 107 CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 108 NORTH AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 109 EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 110 ASIA PACIFIC: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 111 LATIN AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 112 MIDDLE EAST: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 113 GCC COUNTRIES: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 114 LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 115 NORTH AMERICA: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 116 EUROPE: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 117 ASIA PACIFIC: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 118 LATIN AMERICA: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 119 MIDDLE EAST: LIPOSOME-MEDIATED GENE DELIVERY

TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 120 GCC COUNTRIES: LIPOSOME-MEDIATED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 121 CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 122 NORTH AMERICA: CALCIUM PHOSPHATE-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 123 EUROPE: CALCIUM PHOSPHATE-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 124 ASIA PACIFIC: CALCIUM PHOSPHATE-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 125 LATIN AMERICA: CALCIUM PHOSPHATE-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 126 MIDDLE EAST: CALCIUM PHOSPHATE-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 127 GCC COUNTRIES: CALCIUM PHOSPHATE-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 128 DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)

TABLE 129 NORTH AMERICA: DEAE-DEXTRAN-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 130 EUROPE: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 131 ASIA PACIFIC: DEAE-DEXTRAN-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 132 LATIN AMERICA: DEAE-DEXTRAN-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 133 MIDDLE EAST: DEAE-DEXTRAN-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 134 GCC COUNTRIES: DEAE-DEXTRAN-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 135 CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES

MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 136 NORTH AMERICA: CATIONIC POLYMER-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 137 EUROPE: CATIONIC POLYMER-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 138 ASIA PACIFIC: CATIONIC POLYMER-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 139 LATIN AMERICA: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 140 MIDDLE EAST: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 141 GCC COUNTRIES: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 142 OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 143 NORTH AMERICA: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 144 EUROPE: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 145 ASIA PACIFIC: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 146 LATIN AMERICA: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 147 MIDDLE EAST: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 148 GCC COUNTRIES: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 149 PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 150 PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 151 NORTH AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 152 EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 153 ASIA PACIFIC: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 154 LATIN AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 155 MIDDLE EAST: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 156 GCC COUNTRIES: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 157 ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 158 NORTH AMERICA: ELECTROPORATION-BASED GENE DELIVERY

TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 159 EUROPE: ELECTROPORATION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 160 ASIA PACIFIC: ELECTROPORATION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 161 LATIN AMERICA: ELECTROPORATION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 162 MIDDLE EAST: ELECTROPORATION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)	
TABLE 163 GCC COUNTRIES: ELECTROPORATION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 164 MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES	
MARKET, BY REGION, 2022–2029 (USD MILLION)	
TABLE 165 NORTH AMERICA: MICROINJECTION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 166 EUROPE: MICROINJECTION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 167 ASIA PACIFIC: MICROINJECTION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 168 LATIN AMERICA: MICROINJECTION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 169 MIDDLE EAST: MICROINJECTION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)	
TABLE 170 GCC COUNTRIES: MICROINJECTION-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 171 GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY	
REGION, 2022–2029 (USD MILLION)	
TABLE 172 NORTH AMERICA: GENE GUN-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 173 EUROPE: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES	
MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 174 ASIA PACIFIC: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES	
MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 175 LATIN AMERICA: GENE GUN-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	
TABLE 176 MIDDLE EAST: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES	
MARKET, BY REGION, 2022–2029 (USD MILLION)	
TABLE 177 GCC COUNTRIES: GENE GUN-BASED GENE DELIVERY	
TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)	

TABLE 178 OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 179 NORTH AMERICA: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 180 EUROPE: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 181 ASIA PACIFIC: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 182 LATIN AMERICA: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 183 MIDDLE EAST: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 184 GCC COUNTRIES: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 185 GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 186 IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 187 NORTH AMERICA: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 188 EUROPE: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 189 ASIA PACIFIC: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 190 LATIN AMERICA: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 191 MIDDLE EAST: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 192 GCC COUNTRIES: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 193 EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 194 NORTH AMERICA: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 195 EUROPE: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 196 ASIA PACIFIC: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 197 LATIN AMERICA: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 198 MIDDLE EAST: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 199 GCC COUNTRIES: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 200 IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 201 NORTH AMERICA: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 202 EUROPE: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 203 ASIA PACIFIC: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 204 LATIN AMERICA: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 205 MIDDLE EAST: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 206 GCC COUNTRIES: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 207 GENE DELIVERY TECHNOLOGIES MARKET BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 208 GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 209 GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 210 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 211 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 212 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 213 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 214 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 215 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 216 GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY REGION, 2022–2029 (USD MILLION)

TABLE 217 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 218 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 219 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 220 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 221 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY REGION, 2022–2029 (USD MILLION)

TABLE 222 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 223 GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY REGION, 2022–2029 (USD MILLION)

TABLE 224 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 225 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 226 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 227 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 228 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY REGION, 2022–2029 (USD MILLION)

TABLE 229 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 230 GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION)

TABLE 231 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 232 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 233 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 234 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 235 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION)

TABLE 236 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR

VACCINES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 237 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER

THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 238 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 239 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER
THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 240 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 241 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 242 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 243 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 244 GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH
APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 245 GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH
APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 246 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR
RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 247 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR
RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 248 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR
RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 249 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR
RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 250 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR
RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 251 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR
RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 252 GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY &
DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 253 GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY &
DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION)

TABLE 254 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR
DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 255 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG
DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 256 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 257 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 258 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION)

TABLE 259 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 260 GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)

TABLE 261 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 262 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 263 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 264 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 265 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)

TABLE 266 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 267 GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)

TABLE 268 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 269 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 270 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 271 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 272 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)

TABLE 273 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 274 GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)

TABLE 275 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR

GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 276 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 277 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 278 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 279 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)

TABLE 280 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 281 GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)

TABLE 282 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 283 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 284 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 285 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 286 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)

TABLE 287 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 288 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)

TABLE 289 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 290 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 291 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 292 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 293 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)

TABLE 294 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 295 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 296 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 297 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 298 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 299 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 300 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 301 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 302 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 303 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 304 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 305 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 306 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 307 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

TABLE 308 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 309 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 310 GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)

TABLE 311 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 312 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 313 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 314 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 315 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)

TABLE 316 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 317 GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)

TABLE 318 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 319 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 320 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 321 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 322 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)

TABLE 323 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 324 GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)

TABLE 325 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 326 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 327 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 328 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 329 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)

TABLE 330 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 331 GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 332 NORTH AMERICA: KEY MACROINDICATORS

TABLE 333 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 334 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 335 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 336 NORTH AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 337 NORTH AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 338 NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 339 NORTH AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 340 NORTH AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 341 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 342 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 343 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 344 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 345 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 346 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 347 US: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 348 US: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 349 US: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 350 US: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 351 US: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 352 US: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 353 US: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 354 US: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 355 US: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 356 US: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 357 US: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 358 US: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 359 US: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 360 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 361 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 362 CANADA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 363 CANADA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 364 CANADA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 365 CANADA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 366 CANADA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 367 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 368 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY

APPLICATION, 2022–2029 (USD MILLION)

TABLE 369 CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 370 CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 371 CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 372 CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 373 EUROPE: KEY MACROINDICATORS

TABLE 374 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 375 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 376 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 377 EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 378 EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 379 EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 380 EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 381 EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 382 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 383 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 384 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 385 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 386 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 387 EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 388 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY

PRODUCT, 2022–2029 (USD MILLION)

TABLE 389 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 390 GERMANY: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 391 GERMANY: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 392 GERMANY: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 393 GERMANY: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 394 GERMANY: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 395 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 396 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 397 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 398 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 399 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 400 GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 401 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 402 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 403 UK: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 404 UK: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 405 UK: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 406 UK: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 407 UK: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 408 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 409 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 410 UK: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 411 UK: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 412 UK: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 413 UK: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 414 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 415 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 416 FRANCE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 417 FRANCE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 418 FRANCE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 419 FRANCE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 420 FRANCE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 421 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 422 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 423 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 424 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 425 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 426 FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 427 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)

TABLE 428 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022–2029 (USD MILLION)

TABLE 429 ITALY: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES
MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 430 ITALY: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES
MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 431 ITALY: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES
MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 432 ITALY: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY
TYPE, 2022–2029 (USD MILLION)

TABLE 433 ITALY: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY
TYPE, 2022–2029 (USD MILLION)

TABLE 434 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,
2022–2029 (USD MILLION)

TABLE 435 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION)

TABLE 436 ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH
APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 437 ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG
DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 438 ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR
THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 439 ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION)

TABLE 440 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION)

TABLE 441 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022–2029 (USD MILLION)

TABLE 442 SPAIN: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES
MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 443 SPAIN: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES
MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 444 SPAIN: NON-VIRAL VECTOR-BASED GENE DELIVERY
TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 445 SPAIN: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY
TYPE, 2022–2029 (USD MILLION)

TABLE 446 SPAIN: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY
TYPE, 2022–2029 (USD MILLION)

TABLE 447 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 448 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 449 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 450 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 451 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 452 SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 453 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 454 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 455 REST OF EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 456 REST OF EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 457 REST OF EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 458 REST OF EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 459 REST OF EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 460 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 461 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 462 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 463 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 464 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 465 REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 466 ASIA PACIFIC: KEY MACROINDICATORS

TABLE 467 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 468 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 469 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 470 ASIA PACIFIC: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 471 ASIA PACIFIC: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 472 ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 473 ASIA PACIFIC: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 474 ASIA PACIFIC: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 475 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 476 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 477 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 478 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 479 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 480 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 481 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 482 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 483 CHINA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 484 CHINA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 485 CHINA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 486 CHINA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY

TYPE, 2022–2029 (USD MILLION)

TABLE 487 CHINA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 488 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 489 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 490 CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 491 CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 492 CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 493 CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 494 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 495 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 496 JAPAN: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 497 JAPAN: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 498 JAPAN: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 499 JAPAN: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 500 JAPAN: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 501 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 502 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 503 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 504 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 505 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 506 JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 507 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 508 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 509 INDIA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 510 INDIA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 511 INDIA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 512 INDIA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 513 INDIA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 514 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 515 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 516 INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 517 INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 518 INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 519 INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 520 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 521 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 522 SOUTH KOREA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 523 SOUTH KOREA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 524 SOUTH KOREA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 525 SOUTH KOREA: CHEMICAL GENE DELIVERY TECHNOLOGIES

MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 526 SOUTH KOREA: PHYSICAL GENE DELIVERY TECHNOLOGIES

MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 527 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY
METHOD, 2022–2029 (USD MILLION)

TABLE 528 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY
APPLICATION, 2022–2029 (USD MILLION)

TABLE 529 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR
RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 530 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR
DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 531 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR
THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 532 SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY END
USER, 2022–2029 (USD MILLION)

TABLE 533 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY
PRODUCT, 2022–2029 (USD MILLION)

TABLE 534 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,
2022–2029 (USD MILLION)

TABLE 535 AUSTRALIA: VIRAL VECTOR-BASED GENE DELIVERY
TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 536 AUSTRALIA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES
MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 537 AUSTRALIA: NON-VIRAL VECTOR-BASED GENE DELIVERY
TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 538 AUSTRALIA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022–2029 (USD MILLION)

TABLE 539 AUSTRALIA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,
BY TYPE, 2022–2029 (USD MILLION)

TABLE 540 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY
METHOD, 2022–2029 (USD MILLION)

TABLE 541 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY
APPLICATION, 2022–2029 (USD MILLION)

TABLE 542 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR
RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 543 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG
DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 544 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR
THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 545 AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 546 REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 547 REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 548 REST OF ASIA PACIFIC: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 549 REST OF ASIA PACIFIC: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 550 REST OF ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 551 REST OF ASIA PACIFIC: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 552 REST OF ASIA PACIFIC: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 553 REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 554 REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 555 REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 556 REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 557 REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 558 REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 559 LATIN AMERICA: KEY MACROINDICATORS

TABLE 560 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 561 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 562 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 563 LATIN AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 564 LATIN AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 565 LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 566 LATIN AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 567 LATIN AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 568 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 569 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 570 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 571 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 572 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 573 LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 574 BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 575 BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 576 BRAZIL: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 577 BRAZIL: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 578 BRAZIL: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 579 BRAZIL: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 580 BRAZIL: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 581 BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 582 BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 583 BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 584 BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG

DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 585 BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 586 BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 587 MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 588 MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 589 MEXICO: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 590 MEXICO: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 591 MEXICO: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 592 MEXICO: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 593 MEXICO: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 594 MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 595 MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 596 MEXICO: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 597 MEXICO: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 598 MEXICO: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 599 MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 600 REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 601 REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 602 REST OF LATIN AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 603 REST OF LATIN AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 604 REST OF LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 605 REST OF LATIN AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 606 REST OF LATIN AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 607 REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 608 REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 609 REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 610 REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 611 REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 612 REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 613 MIDDLE EAST: KEY MACROINDICATORS

TABLE 614 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

TABLE 615 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 616 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 617 MIDDLE EAST: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 618 MIDDLE EAST: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 619 MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 620 MIDDLE EAST: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 621 MIDDLE EAST: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 622 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 623 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 624 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 625 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 626 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 627 MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 628 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 629 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 630 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 631 GCC COUNTRIES: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 632 GCC COUNTRIES: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 633 GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 634 GCC COUNTRIES: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 635 GCC COUNTRIES: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 636 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 637 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 638 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 639 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 640 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 641 GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 642 SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 643 SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY

MODE, 2022–2029 (USD MILLION)

TABLE 644 SAUDI ARABIA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 645 SAUDI ARABIA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 646 SAUDI ARABIA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 647 SAUDI ARABIA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 648 SAUDI ARABIA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 649 SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 650 SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 651 SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 652 SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 653 SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 654 SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 655 UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 656 UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 657 UAE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 658 UAE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 659 UAE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 660 UAE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 661 UAE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 662 UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 663 UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 664 UAE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 665 UAE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 666 UAE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 667 UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 668 REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 669 REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 670 REST OF GCC COUNTRIES: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 671 REST OF GCC COUNTRIES: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 672 REST OF GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 673 REST OF GCC COUNTRIES: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 674 REST OF GCC COUNTRIES: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 675 REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 676 REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 677 REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 678 REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 679 REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 680 REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 681 REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 682 REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 683 REST OF MIDDLE EAST: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 684 REST OF MIDDLE EAST: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 685 REST OF MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 686 REST OF MIDDLE EAST: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 687 REST OF MIDDLE EAST: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 688 REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 689 REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 690 REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 691 REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 692 REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 693 REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 694 AFRICA: KEY MACROINDICATORS

TABLE 695 AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)

TABLE 696 AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2022–2029 (USD MILLION)

TABLE 697 AFRICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 698 AFRICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 699 AFRICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 700 AFRICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 701 AFRICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY

TYPE, 2022–2029 (USD MILLION)

TABLE 702 AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2022–2029 (USD MILLION)

TABLE 703 AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 704 AFRICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 705 AFRICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)

TABLE 706 AFRICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)

TABLE 707 AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)

TABLE 708 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES

TABLE 709 GENE DELIVERY TECHNOLOGIES MARKET: DEGREE OF COMPETITION

TABLE 710 GENE DELIVERY TECHNOLOGIES MARKET: REGION FOOTPRINT

TABLE 711 GENE DELIVERY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT

TABLE 712 GENE DELIVERY TECHNOLOGIES MARKET: METHOD FOOTPRINT

TABLE 713 GENE DELIVERY TECHNOLOGIES MARKET: APPLICATION FOOTPRINT

TABLE 714 GENE DELIVERY TECHNOLOGIES MARKET: END-USER FOOTPRINT

TABLE 715 GENE DELIVERY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES

TABLE 716 GENE DELIVERY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES

TABLE 717 GENE DELIVERY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024

TABLE 718 GENE DELIVERY TECHNOLOGIES MARKET: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 719 GENE DELIVERY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024

TABLE 720 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW

TABLE 721 THERMO FISHER SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 722 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024

TABLE 723 THERMO FISHER SCIENTIFIC: EXPANSIONS, JANUARY

2021–SEPTEMBER 2024

TABLE 724 DANAHER CORPORATION: COMPANY OVERVIEW

TABLE 725 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS
OFFERED

TABLE 726 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY
2021–SEPTEMBER 2024

TABLE 727 DANAHER CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 728 DANAHER CORPORATION: EXPANSIONS, JANUARY
2021–SEPTEMBER 2024

TABLE 729 MERCK: COMPANY OVERVIEW

TABLE 730 MERCK: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 731 MERCK: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 732 MERCK: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024

TABLE 733 BIO-RAD LABORATORIES: COMPANY OVERVIEW

TABLE 734 BIO-RAD LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS
OFFERED

TABLE 735 AGILENT TECHNOLOGIES: COMPANY OVERVIEW

TABLE 736 AGILENT TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS
OFFERED

TABLE 737 AGILENT TECHNOLOGIES: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 738 REVVITY: COMPANY OVERVIEW

TABLE 739 REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 740 REVVITY: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024

TABLE 741 REVVITY: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 742 QIAGEN: COMPANY OVERVIEW

TABLE 743 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 744 GENSCRIPT: COMPANY OVERVIEW

TABLE 745 GENSCRIPT: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 746 GENSCRIPT: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 747 TAKARA BIO: COMPANY OVERVIEW

TABLE 748 TAKARA BIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 749 TAKARA BIO: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER
2024

TABLE 750 TAKARA BIO: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 751 PROMEGA CORPORATION: COMPANY OVERVIEW

TABLE 752 PROMEGA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS
OFFERED

TABLE 753 BIO-TECHNE: COMPANY OVERVIEW

TABLE 754 BIO-TECHNE: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 755 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024

TABLE 756 LONZA: COMPANY OVERVIEW

TABLE 757 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 758 LONZA: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024

TABLE 759 LONZA: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 760 OXFORD BIOMEDICA: COMPANY OVERVIEW

TABLE 761 OXFORD BIOMEDICA: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 762 OXFORD BIOMEDICA: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024

TABLE 763 OXFORD BIOMEDICA: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 764 OXFORD BIOMEDICA: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2024

TABLE 765 SARTORIUS: COMPANY OVERVIEW

TABLE 766 SARTORIUS: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 767 SARTORIUS: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024

TABLE 768 SARTORIUS: DEALS, JANUARY 2021–SEPTEMBER 2024

TABLE 769 MAXCYTE: COMPANY OVERVIEW

TABLE 770 MAXCYTE: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 771 MAXCYTE: DEALS, JANUARY 2021–SEPTEMBER 2024

List Of Figures

LIST OF FIGURES

FIGURE 1 GENE DELIVERY TECHNOLOGIES MARKET SEGMENTATION AND REGIONAL SCOPE

FIGURE 2 RESEARCH DESIGN

FIGURE 3 BREAKDOWN OF PRIMARIES: GENE DELIVERY TECHNOLOGIES MARKET

FIGURE 4 GENE DELIVERY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023

FIGURE 5 GLOBAL MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023

FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE SHARE ANALYSIS (2023)

FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES

FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

FIGURE 9 GENE DELIVERY TECHNOLOGIES MARKET: CAGR PROJECTIONS

FIGURE 10 DATA TRIANGULATION METHODOLOGY

FIGURE 11 GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)

FIGURE 12 GENE DELIVERY TECHNOLOGIES MARKET, BY MODE, 2024 VS. 2029 (USD MILLION)

FIGURE 13 GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD, 2024 VS. 2029 (USD MILLION)

FIGURE 14 GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)

FIGURE 15 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)

FIGURE 16 GEOGRAPHICAL SNAPSHOT OF GENE DELIVERY TECHNOLOGIES MARKET

FIGURE 17 INCREASED INVESTMENTS IN GENE THERAPY RESEARCH TO DRIVE MARKET

FIGURE 18 RESEARCH APPLICATIONS HELD LARGEST MARKET SHARE IN NORTH AMERICA (2023)

FIGURE 19 VIRAL VECTORS SEGMENT TO DOMINATE MARKET TILL 2029

FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2029

FIGURE 21 GENE DELIVERY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 22 US: PREVALENCE OF CANCER, 2017–2023

FIGURE 23 GENE DELIVERY TECHNOLOGIES MARKET: ECOSYSTEM

FIGURE 24 AVERAGE SELLING PRICE TREND OF GENE DELIVERY
INSTRUMENTS, 2023 (USD THOUSAND)

FIGURE 25 GENE DELIVERY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS

FIGURE 26 GENE DELIVERY TECHNOLOGIES MARKET: SUPPLY CHAIN
ANALYSIS

FIGURE 27 GENE DELIVERY TECHNOLOGIES MARKET: OVERVIEW OF
PATENTING ACTIVITY

FIGURE 28 GENE DELIVERY TECHNOLOGIES MARKET: PORTER'S FIVE
FORCES ANALYSIS

FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS

FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE END USERS

FIGURE 31 REVENUE SHIFT IN GENE DELIVERY TECHNOLOGIES MARKET

FIGURE 32 GENE DELIVERY TECHNOLOGIES MARKET: IMPACT OF AI

FIGURE 33 NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET
SNAPSHOT

FIGURE 34 ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET
SNAPSHOT

FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN GENE DELIVERY
TECHNOLOGIES MARKET, 2021–2023

FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENE DELIVERY
TECHNOLOGIES MARKET, 2023

FIGURE 37 GENE DELIVERY TECHNOLOGIES MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2023

FIGURE 38 GENE DELIVERY TECHNOLOGIES MARKET: COMPANY FOOTPRINT

FIGURE 39 GENE DELIVERY TECHNOLOGIES MARKET: COMPANY EVALUATION
MATRIX (STARTUPS/SMES), 2023

FIGURE 40 EV/EBITDA OF KEY VENDORS

FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS

FIGURE 42 GENE DELIVERY TECHNOLOGIES MARKET: BRAND/PRODUCT
COMPARATIVE ANALYSIS

FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT

FIGURE 45 MERCK: COMPANY SNAPSHOT

FIGURE 46 BIO-RAD LABORATORIES: COMPANY SNAPSHOT

FIGURE 47 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 48 REVVITY: COMPANY SNAPSHOT

FIGURE 49 QIAGEN: COMPANY SNAPSHOT

FIGURE 50 GENSCRIPT: COMPANY SNAPSHOT

FIGURE 51 TAKARA BIO: COMPANY SNAPSHOT

FIGURE 52 BIO-TECHNE: COMPANY SNAPSHOT

FIGURE 53 LONZA: COMPANY SNAPSHOT

FIGURE 54 OXFORD BIOMEDICA: COMPANY SNAPSHOT

FIGURE 55 SARTORIUS: COMPANY SNAPSHOT

FIGURE 56 MAXCYTE: COMPANY SNAPSHOT

I would like to order

Product name: Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) - Global Forecast to 2029

Product link: <https://marketpublishers.com/r/G2EAA40F9BF6EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2EAA40F9BF6EN.html>